| Nov 6 |
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
|
| Nov 6 |
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
|
| Nov 5 |
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
|
| Nov 1 |
Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...
|
| Nov 1 |
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
|
| Nov 1 |
Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...
|
| Oct 31 |
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
|
| Oct 30 |
Q3 2024 BioMarin Pharmaceutical Inc Earnings Call
|
| Oct 28 |
Beyfortus® immunization to protect infants from RSV has begun
|
| Oct 28 |
Regeneron to Report Q3 Earnings: What's in the Offing?
|
